1,207
Participants
Start Date
October 14, 2013
Primary Completion Date
May 19, 2017
Study Completion Date
December 31, 2027
Apalutamide
240 mg tablets administered by mouth on a continuous once daily dosing regimen
Placebo
Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
Birmingham
Anchorage
Chandler
Tucson
Duarte
Fullerton
Laguna Woods
Los Angeles
Orange
Roseville
Sacramento
San Bernardino
San Diego
San Francisco
Santa Monica
Sherman Oaks
Stanford
Tarzana
Torrance
Denver
Englewood
Glenwood Springs
Grand Junction
Washington D.C.
Aventura
Boca Raton
Bradenton
Daytona Beach
Fort Myers
Hialeah
Jacksonville
Miami
New Port Richey
Orlando
Sarasota
St. Petersburg
Wellington
Meridian
Chicago
Decatur
Maywood
Melrose Park
Carmel
Jeffersonville
Muncie
West Des Moines
Westwood
Wichita
Metairie
New Orleans
Annapolis
Baltimore
Rockville
Towson
Boston
Detroit
Lansing
Minneapolis
Royal Oak
Duluth
Bay Saint Louis
Southaven
Kansas City
Missoula
Omaha
Las Vegas
Hooksett
Hackensack
Lawrenceville
Morristown
Mount Laurel
New Brunswick
Voorhees Township
Albuquerque
Albany
Mineola
New York
Oneida
Poughkeepsie
Syracuse
The Bronx
Concord
Greensboro
Greenville
Salisbury
Winston-Salem
Cincinnati
Cleveland
Middleburg Heights
Middletown
Bend
Portland
Tualatin
Bala-Cynwyd
Bryn Mawr
Lancaster
Philadelphia
Pittsburgh
Warwick
Charleston
Greenville
Myrtle Beach
West Columbia
Memphis
Nashville
Abilene
Amarillo
Dallas
Fort Sam Houston
Houston
McAllen
San Antonio
Norfolk
Richmond
Virginia Beach
Burien
Edmonds
Seattle
Tacoma
Green Bay
Madison
Milwaukee
Adelaide
Box Hill
Camperdown
Darlinghurst
Geelong
Gosford
Hobart
Kogarah
Liverpool
Melbourne
Nedlands
Parkville
South Woodville
Southport
Sydney
Tweed Heads
Wollongong
Graz
Innsbruck
Linz
Vienna
Brussels
Ghent
Kortrijk
Leuven
Liège
Ottignies
Calgary
Edmonton
Abbotsford
Kelowna
Vancouver
Victoria
Moncton
Saint John
Halifax
Barrie
Brampton
Brantford
Hamilton
London
North York
Oakville
Ottawa
Owen Sound
Toronto
Gatineau
Granby
Greenfield Park
Laval
Montreal
Pointe-Claire
Québec
Sherbrooke
Liberec
Olomouc
Opava
Pilsen
Prague
Aalborg C
Copenhagen
Odense
Roskilde
Helsinki
Oulu
Seinäjoki
Tampere
Turku
Angers
Besançon
Bordeaux
Caen Cédex 05
Clermont-Ferrand
Hyers
La Roche-sur-Yon
Le Mans
Lille Cedex N/a
Lyon
Marseille
Nice
Nîmes
Paris
Reims
Rennes
Rouen
Saint-Grégoire
Saint-Herblain
Strasbourg
Suresnes
Tours
Vandœuvre-lès-Nancy
Aachen
Bergisch Gladbach
Berlin
Braunschweig
Cologne
Duisburg
Emmendingen
Frankfurt am Main
Göttingen
Greifswald
Hamburg
Hanover
Heidelberg
Heinsberg
Homburg/Saar
Jena
Kiel
Kirchheim unter Teck
Magdeburg
Mainz
Mannheim
Marburg
Mettmann
Müllheim
Münster
Nürtingen
Regensburg
Rostock
Tübingen
Weiden
Wilhelmshaven
Wuppertan
Zirndorf
Budapest
Miskolc
Nyíregyhá
Sopron
Szentes
Haifa
Jeruselem
Kfar Saba
Petah Tikva
Ramat Gan
Tel Aviv
Ẕerifin
Akita
Fukuoka
Gifu
Hakodate
Hiroshima
Hokkaido
Kanazawa
Kashiwa
Kita-Gun
Kobe
Koshigaya
Kumamoto
Kurume
Matsuyama
Nagano
Nagasaki
Nagoya
Niigata
Osaka
Ōsaka-sayama
Sagamihara
Sakura
Sapporo
Shinjuku-Ku
Tokushima
Tokyo
Ube
Wakayama
Yokohama
Alkmaar
Eindhoven
Hoofddorp
Leidschendam
Nijmegen
Rotterdam
Auckland
Christchurch
Hamilton
Nelson
Tauranga
Whangarei
Nordbyhagen
Bialystok
Bydgoszcz
Gdansk
Kutno
Lodz
Poznan
Szczecin
Torun
Warsaw
Wroclaw
Baia Mare
Brasov
Bucharest
Cluj-Napoca
Târgu Mureş
Barnaul
Ivanovo
Moscow
Obninsk
Omsk
Ryazan
Saint Petersburg
Ufa
Yaroslavl
Yekaterinburg
Banská Bystrica
Bratislava
Martin
Nitra
Trenčín
Daegu
Gwangju
Pusan
Seongnam
Seoul
A Coruña
Badalona
Barcelona
Castellon
Girona
Guadalajara
Jerez de la Frontera
Las Palmas de Gran Canaria
Madrid
Málaga
Murcia
Palma de Mallorca
Pamplona
Sabadell
Salamanca
San Sebastián de los Reyes
Santander
Seville
Valencia
Gothenburg
Örebro
Stockholm
Umeå
Uppsala
Kaohsiung City
Taichung
Taipei
Taoyuan
Blackburn
Cambridge
Cardiff
Dundee
Glasgow
Guildford
Leeds
London
Maidstone
Metropolitan Borough of Wirral
Nottingham
Plymouth
Southampton
Surrey
Swansea
Wolverhampton
Lead Sponsor
Aragon Pharmaceuticals, Inc.
INDUSTRY